MedPath

The property Of Expressed Breast Milk In reducing pain during routine Screeing painful Procedure in Pre mature newborn-A Randomised Control Trial

Completed
Conditions
Medical and Surgical, (2) ICD-10 Condition: B998||Other infectious disease,
Registration Number
CTRI/2019/01/017180
Lead Sponsor
Dr samar pratim nayak
Brief Summary

Efficacy of expressed breast milk in reducing pain during routine screening procedure in pre term neonates-a randomised controlled trial

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
60
Inclusion Criteria

All preterm/premature neonates inborn and admitted in NICU / IPD/ well baby,(<37wks,<2500gms) had APGAR scores ⩾7 at 5 minutes; were aged ⩾24 hours; were undergoing venepuncture.

Exclusion Criteria

â–ªAll term neonates â–ªDiagnosed with neurologic problems of any type, if they had received analgesic or sedative drugs within 24 hours of enrolment or neonates having cardio-respiratory compromise, sepsis, central nervous system depression and severe congenital malformations.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome is pain intensity as assessed with the PIPP. The score is assessed at baseline (before starting the procedure),during the procedure and at 1 min and 3 min after the procedure. The PIPP scale is a multidimensional measure developed to assess acute pain in preterm and term infants. It measures gestational age, behavioural state, heart rate, oxygen saturation, and three facial reactions (brow bulge, eye squeeze, nasolabial furrow).The primary outcome is pain intensity as assessed with the PIPP. The score is assessed at baseline (before starting the procedure),during the procedure and at 1 min and 3 min after the procedure. The PIPP scale is a multidimensional measure developed to assess acute pain in preterm and term infants. It measures gestational age, behavioural state, heart rate, oxygen saturation, and three facial reactions (brow bulge, eye squeeze, nasolabial furrow).
Secondary Outcome Measures
NameTimeMethod
Secondary outcomes included crying incidence, percentage of time spent crying during and 3 minutes after lancing, and the incidence of AEs (Eg, nausea, regurgitation, vomiting, choking, de-saturation, tachycardia and bradycardia)Secondary outcomes included crying incidence, percentage of time spent crying during and 3 minutes after lancing, and the incidence of AEs (Eg, nausea, regurgitation, vomiting, choking, de-saturation, tachycardia and bradycardia).

Trial Locations

Locations (1)

DEPARTMENT OF PEDIATRICS

🇮🇳

Bangalore, KARNATAKA, India

DEPARTMENT OF PEDIATRICS
🇮🇳Bangalore, KARNATAKA, India
Dr SAMAR PRATIM NAYAK
Principal investigator
9938058020
samardream@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.